Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Janssen strengthened by completion of Aragon Pharmaceuticals takeover

Janssen strengthened by completion of Aragon Pharmaceuticals takeover

20th August 2013

Janssen has added a number of new compounds to its portfolio following the completion of Johnson and Johnson's takeover of Aragon Pharmaceuticals.

The multinational group – which is Janssen's parent company – has finalised the takeover of Aragon this week, a move that will enhance its capabilities in the field of cancer research.

Aragon is focused on the discovery of drugs to treat hormonally-driven cancers, with future development of compounds from its androgen receptor antagonist programme – including its lead androgen receptor signaling inhibitor ARN-509 – to be managed by Janssen.

Dr Peter Lebowitz, global therapeutic area head for oncology at Johnson and Johnson, said: "The acquisition strengthens our prostate cancer pipeline with a second-generation, potentially best-in-class compound."

Janssen can already boast a strong position in the prostate cancer market thanks to the success of its approved product Zytiga.

The manufacturer received European approval for the use of this drug in the treatment of metastatic castration-resistant prostate cancer earlier this year.ADNFCR-8000103-ID-801627077-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.